Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients.

ABSTRACT:

Background

Congenital fibrinogen deficiency is an ultra-rare disorder in which patients can experience severe and/or frequent bleeding episodes (BEs). Here, we present the largest prospective study to date on the treatment of this disorder.

Methods

Hemostatic efficacy of human fibrinogen concentrate (HFC; FIBRYGA^® , Octapharma AG) for treatment of bleeding or surgical prophylaxis was assessed by investigators and adjudicated by an independent data monitoring and endpoint adjudication committee (IDMEAC) according to a four-point scale, using objective criteria. Thromboelastometry maximum clot firmness (MCF) was also determined.

Results

Twenty-five afibrinogenemia patients were treated with HFC: 24 for on-demand treatment of 89 BEs, and nine as prophylaxis fo

SUBMITTER: Lissitchkov T 

PROVIDER: S-EPMC7187153 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature